Venus Remedies Limited

NSE VENUSREM.NS

Venus Remedies Limited Shareholders' Equity for the year ending March 31, 2024: USD 58.45 M

Venus Remedies Limited Shareholders' Equity is USD 58.45 M for the year ending March 31, 2024, a 4.36% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Venus Remedies Limited Shareholders' Equity for the year ending March 31, 2023 was USD 56.01 M, a -3.44% change year over year.
Venus Remedies Limited Shareholders' Equity for the year ending March 31, 2022 was USD 58.01 M, a 6.11% change year over year.
Venus Remedies Limited Shareholders' Equity for the year ending March 31, 2021 was USD 54.67 M, a 27.40% change year over year.
Venus Remedies Limited Shareholders' Equity for the year ending March 31, 2020 was USD 42.91 M, a -10.32% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NSE: VENUSREM.NS

Venus Remedies Limited

CEO	Mr. Ashutosh Jain B.A., LL.B
IPO Date	Dec. 20, 2006
Location	India
Headquarters	Plot 51-52, Industrial Area
Employees	1,187
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Key trends

Past 5 years